[HTML][HTML] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - Trials, 2022 - Springer
Background The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
A Manomaipiboon, K Pholtawornkulchai… - Trials, 2022 - search.ebscohost.com
Background: The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - Trials, 2022 - search.proquest.com
Background The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
[PDF][PDF] E cacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial
A Manomaipiboon, K Pholtawornkulchai, S Pupipatpab… - assets-eu.researchsquare.com
The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
[HTML][HTML] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - …, 2022 - trialsjournal.biomedcentral.com
The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
[HTML][HTML] Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial
A Manomaipiboon, K Pholtawornkulchai, S Pupipatpab… - 2022 - europepmc.org
The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - 2022 - pubmed.ncbi.nlm.nih.gov
Background The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
Efficacy and safety of ivermectin in the treatment of mild-to-moderate COVID-19 infection: A randomized, double blind, placebo, controlled trial
A Manomaipiboon, K Pholtawornkulchai, S Pupipatpab… - researchsquare.com
The emergent outbreak of coronavirus disease (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement for …
[PDF][PDF] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - 2022 - scienceopen.com
Background: The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
[HTML][HTML] Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
A Manomaipiboon, K Pholtawornkulchai… - Trials, 2022 - ncbi.nlm.nih.gov
Background The emergent outbreak of coronavirus disease (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emphasized the requirement …